Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study.

Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study.

Urotoday December 16, 2019 Urotoday reporting the multicentric study paper on SoracteLite for the management of BPH. Read the article here. Leggi tutto
Tuscany research, Golden Pegasus price for Leonardo Masotti

Tuscany research, Golden Pegasus price for Leonardo Masotti

Toscanamedianews November 3, 2019 Professor Leonardo Masotti, founder of El.En. Group and Chairman of Elesta, received yesterday the Tuscany Research Prize for his Career as Scientist from the Minister of Public Education. Congratulations from the entire Elesta team!... Leggi tutto
Cambridge Prostate mpMRI & Biopsy Course

Cambridge Prostate mpMRI & Biopsy Course

November 19, 2019 The course will take place in Villa Mondragone, Frascati (RM) on November 19. Click here to visit the course website. Leggi tutto
ModìLite on Thyroworld

ModìLite on Thyroworld

We are proud to announce that ModìLite treatment has been reported on the September edition of ThyroWorld Magazine from Thyroid Federation International! Please click here to download a copy of the magazine, while you can read the article on ModìLite at page... Leggi tutto
ETA 2019

ETA 2019

September 7-10, 2019 The 42° edition of the European Thyroid Association Congress will take place from September 7th to September 10th at BCC – Budapest Congress Centre in Budapest. Come and visit our stand n. 5 to discover the advantages of ModìLite! Click here to... Leggi tutto
Choose language

Please make your choiche

Please select your country/geographic area

The USA version of Elesta website is not yet available.